Human Breast Cancer, Triple Positive (ER+/PR+/Her2+), FFPE Sections

Human Triple Positive (ER+PR+HER2+) Breast Cancer is a distinct subtype characterized by the presence of three specific receptors: Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2) in breast cancer cells. This implies that the cancer cells in the breast tissue express receptors for estrogen, progesterone, and HER2.

In the realm of breast cancer, the status of these receptors holds critical importance in determining treatment strategies. In Triple Positive cases, cancer cells respond to hormones such as estrogen and progesterone, along with the HER2 protein. This valuable information guides medical professionals in tailoring therapies that specifically target these receptors, such as hormone therapy or HER2-targeted therapies.

Understanding the molecular characteristics of breast cancer, particularly its receptor status, is pivotal in developing personalized and effective treatment plans for individuals diagnosed with Triple Positive breast cancer.

VitroVivo Bitech provides the FFPE sections of human triple positive (ER+PR+HER2+) breast cancer to enhance your breast cancer research. These human breast cancer FFPE sections are mounted on positively charged glass slides and sectioned at 5 µm thickness. These FFPE slides can be used to perform RNA scope ISH, FISH IF, IHC and NGS, etc.

Product Name	SKU#	Pathology Dx	ER,PR & HER2 IHC Data
Human Breast Cancer, Triple Positive (ER+/PR+/Her2+), (Invasive ductal carcinoma) FFPE Sections	HuPS-02005T1	Human breast Invasive ductal carcinoma	ER(30% +), PR(30%+), CK-7(+),P53(-), CK5/6(-), Ki67(25% +),Her2 (++), VEGF(+), E-cad(+)
Human Breast Cancer, Triple Positive (ER+/PR+/Her2+), (Invasive ductal carcinoma) FFPE Sections	HuPS-02006T	Invasive duct carcinoma	ER(80% +), PR(60%+), Her2 (15%+)
Human Breast Cancer, Triple Positive (ER+/PR+/Her2+), (Invasive ductal carcinoma) FFPE Sections	HuPS-02007T	Invasive duct carcinoma	ER(60% +), PR(25%+), Her2(15%+)
Human Breast Cancer, Triple Positive (ER+/PR+/Her2+), (Invasive ductal carcinoma) FFPE Sections	HuPS-02008T	Invasive duct carcinoma	ER(+), PR(+),Her2 (Equivocal)
Human Breast Cancer, Triple Positive (ER+/PR+/Her2+), (Invasive ductal carcinoma) FFPE Sections	HuPS-02009T	Invasive duct carcinoma	ER(70% ++), PR(15%+), Her2(Score2)
Human Breast Cancer, Triple Positive (ER+/PR+/Her2+), (Invasive ductal carcinoma) FFPE Sections	HuPS-02010T1	Invasive duct carcinoma	ER(2% +), PR(2%+), Her2(Score3)
Human Breast Cancer, Triple Positive (ER+/PR+/Her2+), (Invasive ductal carcinoma) FFPE Sections	HuPS-02010T2	Invasive duct carcinoma	ER(2% +), PR(2%+), Her2(Score3)
Human Breast Cancer, Triple Positive (ER+/PR+/Her2+), (Infiltrating duct carcinoma) FFPE	HuPS-02011T	Infiltrating duct carcinoma	ER(85%+++), PR(65%+++), Her2(Score -3)
Human Breast Cancer, Triple Positive (ER+/PR+/Her2+), (Infiltrating duct carcinoma) FFPE	HuPS-02012T	Infiltrating duct carcinoma	ER(100% +++), PR(80%+++), Her2 (Score 2+)
Human Breast Cancer, Triple Positive (ER+/PR+/Her2+), (Invasive high grade mammary CA with medullary features) FFPE Sections	HuPS-02013T	Invasive high grade mammary CA with medullary features	ER(95% +++), PR(90%+++), Her2 (Score -3)
Human Breast Cancer, Triple Positive (ER+/PR+/Her2+), (Multifocal infiltrating duct carcinoma) FFPE Sections	HuPS-02014T	Multifocal infiltrating duct carcinoma	ER(95% +++), PR(50%+++), Her2 (Score 2+)
Human Breast Cancer, Triple Positive (ER+/PR+/Her2+), (Infiltrating duct carcinoma) FFPE Sections	HuPS-02015T	Infiltrating duct carcinoma	ER(80% ++), PR(70%+++), Her2 (Score 2)